SAGEMCOM
14.9.2023 16:49:27 CEST | Business Wire | Press release
Sagemcom, a world leader in video, audio, and broadband solutions to operators, today announced that its newest version of its ground-breaking Video Soundbox™ is powered by RDK open-source software.
RDK is an open-source software solution, deployed on more than 100 million devices worldwide, that standardizes core functions and telemetry used in broadband, video, and IoT connected devices. Last year, Sagemcom announced that it became a member of the prestigious RDK Technical Advisory Board and its commitment to embed RDK software throughout its full portfolio of broadband CPE devices (PON, FTTH, DOCSIS, DSL and 5G). Sagemcom also is adopting RDK software within video products, including the Video Soundbox—an all-in-one audio/video entertainment hub, embedding premium speakers and woofer, Dolby Atmos and Dolby Vision certified, with powerful, natural and authentic audio fine-tuned by Bang & Olufsen.
“With the home entertainment market constantly evolving, Sagemcom is always looking for ways to bring innovative and high-quality products to its customers in the best ways possible,” said Olivier Taravel, Senior Executive Video President, Audio Video Solutions BU, Sagemcom. “Our commitment to RDK is foundational to our product roadmaps, and we’re excited to offer the Video Soundbox as the latest product available for RDK operators around the world. We’re also confident that the Video Soundbox is a true product differentiator that can help operators increase customer satisfaction with its high NPS and reduce churn.”
“Sagemcom remains at the forefront of product and service modernization for today’s pay TV and broadband service providers,” said Jason Briggs, RDK President and General Manager. “We’re honored to have them as members of our RDK Technical Advisory Board, and we are particularly pleased to see them adopt RDK into a device as innovative as their Video Soundbox.”
Video Soundbox
Whether watching a movie, streaming music, or just enjoying some background sounds, the Video Soundbox delivers an audio experience that can immerse consumers in their favorite content and bring it to life. Video Soundbox is Dolby Atmos and Dolby Vision certified, meaning it can deliver rich, spatialized sound and crystal clear 4K HDR pictures. This makes it the perfect choice for a home cinema setup, as it allows viewers to fully experience the depth and clarity of modern content.
The Video Soundbox also offers far-field voice control and voice assistance services through its embedded microphones. This makes it easy to use and convenient for multi-user and multi-language scenarios. With the Video Soundbox, consumers can change the volume, switch channels, or play their favorite playlist just by speaking a command.
One of the most compelling reasons for operators to consider deploying the Video Soundbox is its high net promoter score (NPS). This metric measures customer satisfaction and loyalty, and the Video Soundbox consistently shows consumers to be extremely satisfied, which makes it a great retention tool for operators.
For more information on Audio Video Solutions: contact-AVS@sagemcom.com
Additional information about RDK is available at www.rdkcentral.com.
About Sagemcom
Thanks to the innovative solutions designed and built by our people, Sagemcom provides access to broadband Internet, entertainment and managed energy supply to the greatest number all over the world.
As a “mission-driven company” since January 2022, Sagemcom makes sure that the design, construction and use of these solutions are sustainable, and fulfil the environmental and societal commitments that are known and shared by all our employees, partners and stakeholders. Sagemcom is the world leader in Broadband products and solutions, and the European leader in smart metering.
www.sagemcom.com // https://www.linkedin.com/company/sagemcom // www.facebook.com/SagemcomOfficial // https://twitter.com/Sagemcom // https://www.instagram.com/sagemcom_inside.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230915547929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom